ALEC · XBRL financial data
Alector financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (ALEC's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | year only | 16 | 15 | 15 | year only | 4 | 8 | 3 | 6* | — | — |
| Revenue from contracts with customers | 9 | 15* | 16 | 15 | 15 | 54* | 4 | 8 | 3 | 6* | 1 | 3 |
| Research and development | 46 | 48* | 45 | 46 | 48 | 46* | 34 | 28 | 29 | 32* | 18 | 19 |
| General and administrative | 13 | 15* | 14 | 14 | 16 | 15* | 15 | 14 | 12 | 13* | 8 | 8 |
| Total operating expenses | 60 | 63* | 60 | 61 | 64 | 61* | 48 | 42 | 41 | 46* | 26 | 28 |
| Operating income (loss) | (51) | (47)* | (44) | (46) | (48) | (7)* | (45) | (34) | (38) | (40)* | (25) | (24) |
| Other income (expense) | 7 | 8* | 8 | 7 | 6 | 5* | 4 | 4 | 3 | 2* | 2 | 2 |
| Income tax expense (benefit) | 1 | 2* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Net income (loss) | (44) | (41)* | (36) | (39) | (42) | (2)* | (40) | (31) | (35) | (37)* | (23) | (23) |
| Earnings per share, basic USD per share | (0.53) | (0.49)* | (0.38) | (0.40) | (0.43) | (0.02)* | (0.41) | (0.30) | (0.34) | (0.34)* | (0.21) | (0.21) |
| Earnings per share, diluted USD per share | (0.53) | (0.49)* | (0.38) | (0.40) | (0.43) | (0.02)* | (0.41) | (0.30) | (0.34) | (0.34)* | (0.21) | (0.21) |
| Weighted average shares, basic millions of shares | 84 | 84* | 94 | 97 | 98 | 98* | 99 | 100 | 103 | 110* | 111 | 111 |
| Weighted average shares, diluted millions of shares | 84 | 84* | 94 | 97 | 98 | 98* | 99 | 100 | 103 | 110* | 111 | 111 |
Balance sheet
CSVFiscal quarters (ALEC's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 102 | 75 | 73 | 48 | 37 | 33 | 38 | 45 | 77 | 66 | 77 | 60 |
| Marketable securities | 487 | 474 | 490 | 456 | 420 | 380 | 317 | 263 | 215 | 190 | 130 | 113 |
| Prepaid and other current assets | 14 | 17 | 19 | 16 | 12 | 11 | 12 | 12 | 9 | 10 | 9 | 7 |
| Total current assets | 613 | 566 | 581 | 520 | 469 | 425 | 367 | 319 | 300 | 266 | 215 | 180 |
| Property and equipment, net | 23 | 22 | 21 | 20 | 18 | 17 | 16 | 14 | 13 | 11 | 10 | 9 |
| Right-of-use asset | 26 | 25 | 24 | 23 | 21 | 20 | 19 | 17 | 16 | 14 | 13 | 12 |
| Total assets | 672 | 622 | 635 | 571 | 516 | 468 | 408 | 356 | 335 | 293 | 240 | 203 |
| Accounts payable | 5 | 4 | 5 | 4 | 5 | 2 | 2 | 2 | 5 | 2 | 1 | 2 |
| Accrued liabilities | 30 | 30 | 19 | 23 | 26 | 29 | 17 | 14 | 18 | 19 | 11 | 7 |
| Current portion of long-term debt | — | — | — | — | — | — | — | — | — | 0 | — | 10 |
| Total current liabilities | 155 | 178 | 165 | 148 | 143 | 125 | 110 | 84 | 80 | 70 | 41 | 34 |
| Long-term debt | — | 0 | — | — | — | 9 | 9 | 10 | 10 | 9 | 8 | 0 |
| Lease liability, non-current | 32 | 30 | 29 | 28 | 26 | 24 | 23 | 21 | 19 | 17 | 16 | 14 |
| Total liabilities | 510 | 488 | 457 | 420 | 397 | 342 | 314 | 285 | 278 | 263 | 230 | 213 |
| Accumulated deficit | (669) | (710) | (746) | (785) | (827) | (829) | (870) | (900) | (935) | (972) | (995) | (1,018) |
| Total stockholders' equity | 163 | 134 | 179 | 151 | 119 | 127 | 95 | 71 | 58 | 31 | 10 | (10) |
| Total liabilities and equity | 672 | 622 | 635 | 571 | 516 | 468 | 408 | 356 | 335 | 293 | 240 | 203 |
| Common shares outstanding (cover page) millions of shares | 84 | 96 | 96 | 97 | 98 | 99 | 100 | 101 | 109 | 110 | 111 | 112 |
Cash flows
CSVFiscal quarters (ALEC's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (44) | (41)* | (36) | (39) | (42) | (2)* | (40) | (31) | (35) | (37)* | (23) | (23) |
| Stock-based compensation | 10* | 12* | 10 | 10* | 9* | 10* | 8 | 7* | 6* | 5* | 3 | 3* |
| Net cash from operating activities | (47)* | (46)* | (61) | (63)* | (51)* | (55)* | (61) | (49)* | (33)* | (42)* | (50) | (34)* |
| Purchases of property and equipment | (0)* | 0* | 1 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* |
| Net cash from investing activities | 17* | 18* | (12) | 37* | 40* | 41* | 66 | 56* | 50* | 26* | 61 | 17* |
| Proceeds from issuing common stock | — | — | — | — | — | 0* | — | — | — | 5* | — | — |
| Net cash from financing activities | 0* | 1* | 71 | 1* | 0* | 10* | 0 | 0* | 15* | 5* | 0 | 0* |
| Net change in cash | (30)* | (27)* | (2) | (25)* | (10)* | (4)* | 5 | 7* | 32* | (11)* | 11 | (17)* |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Alector | 60 | 3.3 | (34)* | 111.7M | 5.1 quarters | 10-QJun 30, 2026 |
| Protalix BioTherapeutics | 27 | 20 | (10)* | 80.6M | 2.6 quarters | 10-QJun 30, 2026 |
| Fate Therapeutics | 32 | 2.1 | (23) | 119.8M | 6.6 quarters | 10-QJun 30, 2026 |
| Caribou Biosciences | 26 | 1.5 | (23)* | 107.2M | 4.9 quarters | 10-QJun 30, 2026 |
| Protara Therapeutics | 17 | not reported | (15)* | 59.1M | 9.3 quarters | 10-QJun 30, 2026 |
| TuHURA Biosciences | 1 | not reported | (8.6)* | 63.7M | 0.1 quarters | 10-QJun 30, 2026 |
| Enanta Pharmaceuticals | 33 | 14 | (10)* | 29.1M | 19.0 quarters | 10-QJun 30, 2026 |
| Kodiak Sciences | 126 | not reported | (46)* | 62.8M | 2.7 quarters | 10-QJun 30, 2026 |
| Galectin Therapeutics | 13 | not reported | (2.4)* | 100.8M | 5.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.